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ADA

:   anti‐drug antibody

CGRP

:   calcitonin gene‐related peptide

CM

:   chronic migraine

EM

:   episodic migraine

EMA

:   European Medicines Agency

FDA

:   Food and Drug Administration

mAb

:   monoclonal antibody

MMD

:   monthly migraine day

NAb

:   neutralizing antibody

1. INTRODUCTION {#prp2567-sec-0001}
===============

Migraine is a highly prevalent neurological disorder that is associated with substantial clinical and socioeconomic impact.[1](#prp2567-bib-0001){ref-type="ref"} Calcitonin gene‐related peptide (CGRP) is a neuropeptide, with two major forms (α and β), that is widely distributed in nociceptive pathways in the central and peripheral nervous systems and plays a key role in the signaling pathways involved in the pathophysiology of migraine.[2](#prp2567-bib-0002){ref-type="ref"}, [3](#prp2567-bib-0003){ref-type="ref"}, [4](#prp2567-bib-0004){ref-type="ref"} Thus, CGRP and one of the CGRP receptors in the calcitonin family have been targets of therapeutic interventions for the prevention of migraine.[4](#prp2567-bib-0004){ref-type="ref"}, [5](#prp2567-bib-0005){ref-type="ref"}

Population pharmacokinetic (PK) analyses guide drug development and inform recommendations on individualized treatment (eg, dose adjustments) by assessing the variability in PK of a drug in individuals of a population, as well as variability based on various characteristics of individuals.[6](#prp2567-bib-0006){ref-type="ref"}, [7](#prp2567-bib-0007){ref-type="ref"} Dose‐response and exposure‐response analyses further the understanding of drug effects by evaluating which dose and exposure levels are associated with efficacious benefit with the least risk of adverse effects.[6](#prp2567-bib-0006){ref-type="ref"} Considering that migraine is a heterogeneous disorder,[8](#prp2567-bib-0008){ref-type="ref"}, [9](#prp2567-bib-0009){ref-type="ref"} it is valuable to assess whether a migraine‐targeted therapy exhibits variability across individuals to appropriately individualize treatment for optimal outcomes.

Eptinezumab (ALD403) is a humanized anti‐CGRP antibody with an IgG1 backbone that binds to both the α and β forms of CGRP and is currently under development for migraine prevention. In controlled clinical studies, it has demonstrated efficacy compared to placebo in the prevention of migraine in patients with episodic migraine (EM) and chronic migraine (CM).[10](#prp2567-bib-0010){ref-type="ref"}, [11](#prp2567-bib-0011){ref-type="ref"}, [12](#prp2567-bib-0012){ref-type="ref"}, [13](#prp2567-bib-0013){ref-type="ref"}, [14](#prp2567-bib-0014){ref-type="ref"} This report describes a population PK modeling analysis conducted for the IV administration of eptinezumab at single doses of 10‐1000 mg in healthy subjects and in patients with EM and CM from eight studies in the eptinezumab clinical program.[11](#prp2567-bib-0011){ref-type="ref"}, [12](#prp2567-bib-0012){ref-type="ref"}, [13](#prp2567-bib-0013){ref-type="ref"} A further goal was to assess the dose‐ and exposure‐response relationships of selected endpoints in patients with EM and CM who received eptinezumab.

2. MATERIALS AND METHODS {#prp2567-sec-0002}
========================

2.1. Study population {#prp2567-sec-0003}
---------------------

The eight studies with available PK and pharmacodynamic (PD) data are listed in Table [1](#prp2567-tbl-0001){ref-type="table"}. All eight studies were included in the population PK analysis and included a total of 2123 patients and healthy volunteers who received eptinezumab. The PK dataset included only PK information related to IV administration of eptinezumab over approximately 30 minutes to 1 hour at dose levels of 10‐1000 mg in healthy subjects and in patients with EM and CM. The concentrations of free eptinezumab were measured in plasma from all eptinezumab‐treated patients using validated methods. Three clinical studies (CLIN‐005, CLIN‐006, and CLIN‐011), involving 2543 patients who received eptinezumab at doses ranging from 10 to 300 mg or placebo, provided efficacy data for the exposure‐response analysis. This exposure‐response analysis population is larger than the PK population because it included patients who received placebo.

###### 

Pharmacokinetic and exposure‐response analyses population

  Study                                                                 Design         IV Duration   Eptinezumab dose (mg)   Overall                                       
  --------------------------------------------------------------------- -------------- ------------- ----------------------- --------- ----- ----- ----- ----- ----- ----- ------
  PK population                                                                                                                                                            
  CLIN‐001                                                              P1, SAD, HV    1 hour        N/A                     4         6     5     6     6     20    6     53
  CLIN‐002                                                              P1b, SD, FEM   1 hour        N/A                     N/A       N/A   N/A   N/A   N/A   N/A   81    81
  CLIN‐005                                                              P2, SD, CM     1 hour        N/A                     N/A       N/A   125   119   121   119   N/A   484
  CLIN‐006                                                              P3, MD, FEM    1 hour        N/A                     N/A       N/A   N/A   211   216   219   N/A   646
  CLIN‐010                                                              P1, SD, HO/O   1 hour        N/A                     N/A       N/A   N/A   N/A   16    N/A   N/A   16
  CLIN‐011                                                              P3, MD CM      1 hour        N/A                     N/A       N/A   N/A   N/A   354   349   N/A   703
  CLIN‐012                                                              P1, SD, T1DM   1 hour        N/A                     N/A       N/A   N/A   N/A   14    N/A   N/A   14
  CLIN‐013                                                              P3, MD, CM     30 minutes    N/A                     N/A       N/A   N/A   N/A   N/A   126   N/A   126
  Overall                                                                                            N/A                     4         6     130   336   727   833   87    2123
  Exposure‐response analyses population (primary endpoint weeks 1‒12)                                                                                                      
  CLIN‐005                                                              P2, SD, CM     1 hour        122                     N/A       N/A   125   119   121   119   N/A   606
  CLIN‐006                                                              P3, MD FEM     1 hour        222                     N/A       N/A   N/A   211   216   219   N/A   868
  CLIN‐011                                                              P3, MD CM      1 hour        366                     N/A       N/A   N/A   N/A   354   349   N/A   1069
  Overall                                                                                            710                     0         0     125   330   691   687   N/A   2549

Abbreviations: CM, chronic migraine; FEM, frequent episodic migraine; HO/O, healthy overweight/obese; HV, healthy volunteers; MD, multiple dose; N/A, not applicable; P, phase; SAD, single ascending dose; SD, single dose; T1DM, type 1 diabetes mellitus.
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2.2. Population pharmacokinetics {#prp2567-sec-0004}
--------------------------------

### 2.2.1. Model {#prp2567-sec-0005}

The current population PK analysis was based on the recommendations provided in key guidance documents from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).[6](#prp2567-bib-0006){ref-type="ref"}, [7](#prp2567-bib-0007){ref-type="ref"} The population PK modeling process used a nonlinear mixed‐effects approach as described in Section [3](#prp2567-sec-0009){ref-type="sec"}b of the FDA guidance.[7](#prp2567-bib-0007){ref-type="ref"} The population PK analysis was performed using Phoenix^®^ NLME™ 8.0 (nonlinear mixed‐effects modeling \[NLME\]) (Certara USA, Inc) with First‐Order Conditional Estimation ‐ Extended Least Squares (FOCE‐ELS) and used the INTERACTION option. FOCE involves optimization of marginal log likelihood(s) using a series of iterations. The population PK model consisted of the following: (a) a description of the relationships between plasma concentration and time; (b) a variance component characterizing inter‐individual variability and, if required, inter‐occasion variability in model parameters; and (c) modeling of residual unexplained variability using additive, proportional, or additive and proportional models.

Figure [1](#prp2567-fig-0001){ref-type="fig"} illustrates the methodology used in the population PK analyses. A two‐compartment model was used as a starting point, although other models were also investigated (one‐ and three‐compartment models). The models had the following form: $$C_{\mathit{ij}} = m{(D_{i},\, t_{j},\Phi_{i})} \cdot {(1 + \varepsilon_{p,ij})} + \varepsilon_{a,ij}$$ $$\Phi_{I} = {(\Phi_{I1},\ldots,\Phi_{\mathit{Ip}})}$$where *Cij* is the concentration level at the *j* ^th^ collection time *t~j~* for subject *i*; m represents the set of equations that define the model; *Di* represents dosing history for subject *i*; Φ*i* is the vector of *p* PK parameters for subject *i*; and ε*~p,ij~* and ε*~a,ij~* are the proportional and additive random residual error terms, respectively, associated with *j^th^* concentration for subject *i*.

![Overview of population pharmacokinetic (PK) model development of eptinezumab](PRP2-8-e00567-g001){#prp2567-fig-0001}

### 2.2.2. Covariate analysis {#prp2567-sec-0006}

Intrinsic and extrinsic covariates influencing eptinezumab clearance (CL) and volume of distribution (*V* ~D~) were explored using the stepwise forward addition procedure (*α* = .05) and backward elimination process (*α* = .01), with a priori statistical significance criteria for the forward and backward search directions. The potential impacts upon eptinezumab exposure by covariate effects in the final model were characterized using a forest plot to facilitate optimal understanding of covariate effects (as per FDA requirements).[15](#prp2567-bib-0015){ref-type="ref"} The following intrinsic and extrinsic covariates were considered: demographics (age, body weight, sex, race, disease status \[healthy subjects vs episodic or chronic migraine patients\]), dose, baseline number of migraine days, immunogenicity (presence of anti‐drug antibodies \[ADAs\] and neutralizing antibodies \[NAbs\]), and concomitant preventive headache/migraine medications (ie, beta‐blockers, topiramate, valproate, tricyclic antidepressants).

### 2.2.3. Model validation/qualification {#prp2567-sec-0007}

Model validation/qualification was performed according to FDA and EMA guidance for industry.[6](#prp2567-bib-0006){ref-type="ref"}, [16](#prp2567-bib-0016){ref-type="ref"} The quality‐of‐fit was evaluated using a standard model discrimination process including statistical criteria such as maximum likelihood objective function (MOF) as well as pertinent graphical representations of goodness‐of‐fit (eg, fitted and observed concentrations vs time, conditional weighted residuals).[17](#prp2567-bib-0017){ref-type="ref"} Diagnostic plots were derived, including (a) Observed data (DV) vs population predicted data (PRED) and individual predicted data (IPRED) with a line of unity and a locally weighted scatter plot smoothing (LOESS) line; (b) DV vs time after first administration (time) and DV vs TAD with LOESS lines for IPRED and PRED; (c) Conditional weighted residuals (CWRES) vs PRED, vs TAD and vs time; (d) Individual concentration‐time profiles for all subjects comparing observed concentrations, the individual prediction line, and the population prediction line; (e) Quantile‐quantile plot of CWRES (QQ plot); and (f) Individual weighted residuals (IWRES) vs IPRED, vs TAD and vs time. Based on the estimates of the final population PK model, concentration‐time profiles of eptinezumab were simulated (\~1000 replicates). The medians, as well as 5th and 95th percentiles, of the simulated concentrations were computed with their respective 90th percentile intervals.

### 2.2.4. Dose‐ and exposure‐response modeling {#prp2567-sec-0008}

Dose‐response relationships were explored prior to performing exposure‐response analysis. The primary dose‐response analysis was for the change in monthly migraine days (MMD) over weeks 1‐12. PK parameters from the final population PK model were used to derive exposure metrics: area under the curve from time 0 to 12 weeks (AUC~0‐12wk~), maximum concentration (*C* ~max~), average concentration (*C* ~avg~), and trough concentration (*C* ~trough~). The exposure‐response relationship of plasma eptinezumab was evaluated using these single‐dose exposure parameters and the change in frequency of MMD (weeks 1‐12) from studies CLIN‐005, CLIN‐006, and CLIN‐011.[11](#prp2567-bib-0011){ref-type="ref"}, [12](#prp2567-bib-0012){ref-type="ref"}, [13](#prp2567-bib-0013){ref-type="ref"} A saturable inhibitory maximum‐effect (*E* ~max~) model was used to assess relationships between the exposure metrics of eptinezumab and the reduction in MMD. An example for AUC~0‐12wk~ is as follows: *E*0 + *I* ~max~ × AUC/(AUC~50~ + AUC) where *E*0 is the predicted effect when AUC = 0 (ie, placebo effect), *I* ~max~ is the maximum inhibitory effect, and AUC~50~ is the AUC achieving the half‐maximal change in effect and AUC is the area under the concentration‐time curve for eptinezumab.

A placebo‐anchored approach was used because this method was shown to be more statistically powerful than a simple placebo‐corrected analysis for use in dose‐response analyses.[18](#prp2567-bib-0018){ref-type="ref"}

Key secondary efficacy endpoints were also assessed in the exposure‐response analysis. These endpoints included ≥75% migraine responder rates (weeks 1‐4), ≥75% migraine responder rate (weeks 1‐12), and ≥50% migraine responder rates (weeks 1‐12). A logistic regression analysis was performed to explore associations between eptinezumab exposures (ie, AUC~0‐12wk,~ *C* ~avg~, *C* ~trough~, *C* ~max~) and these categorical endpoints.

3. RESULTS {#prp2567-sec-0009}
==========

3.1. Patients/subjects {#prp2567-sec-0010}
----------------------

A total of 2123 patients and subjects from eight clinical studies who received eptinezumab were included in the population PK analysis. The number of patients/subjects receiving each dose of eptinezumab included in the PK and exposure‐response populations from each study is summarized in Table [1](#prp2567-tbl-0001){ref-type="table"}. Patients/subjects were primarily female (83.8%), white (88.5%), and ADA‐negative (83.8%) at baseline, with a median age of 39.0 years (18‐71 years) and a body weight of 74.2 kg (39.2‐190 kg). Renal function was normal in 55.3% of patients/subjects, with mild or moderate decreases in estimated glomerular filtration rate (eGFR) in 41.9% and 2.7% of patients/subjects, respectively. The average MMD during the screening period of studies CLIN‐005, CLIN‐006, and CLIN‐011[11](#prp2567-bib-0011){ref-type="ref"}, [12](#prp2567-bib-0012){ref-type="ref"}, [13](#prp2567-bib-0013){ref-type="ref"} was approximately 14 days (CLIN‐005, 16.5 MMD; CLIN‐006, 8.7 MMD; CLIN‐011, 16.1 MMD).

3.2. Population pharmacokinetics {#prp2567-sec-0011}
--------------------------------

The concentration‐time profile of eptinezumab following IV dosing was adequately characterized by a two‐compartment model with linear elimination. Population and individual predicted concentrations of eptinezumab from the final model suggest reasonable agreement with the observed data with high and low concentration values evenly distributed around the line of identity. Additionally, conditional weighted residuals values (ie, CWRES vs predicted concentration or time) are homogeneously distributed around 0 with only a small proportion of points exceeding ±4. Goodness‐of‐fit plots derived with the final population PK model of eptinezumab are presented in Figure [2](#prp2567-fig-0002){ref-type="fig"}. The visual predictive check (VPC) of eptinezumab concentrations is presented in Figure [3](#prp2567-fig-0003){ref-type="fig"}. Observed median and upper/lower 90th percentiles of observed eptinezumab concentrations were contained within the model‐predicted ranges (shaded areas). These results confirm the adequacy of the final population PK model in predicting eptinezumab concentrations.

![Goodness‐of‐fit for final model of eptinezumab](PRP2-8-e00567-g002){#prp2567-fig-0002}

![Visual predictive check by study: (A) linear plots and (B) semi‐log plots](PRP2-8-e00567-g003){#prp2567-fig-0003}

A stepwise covariate analysis was performed to identify sources of variability in PK parameters of eptinezumab. Consistent with the pharmacokinetics that are typical for monoclonal antibodies (mAbs),[19](#prp2567-bib-0019){ref-type="ref"} CL and the central volume of distribution (Vc) of eptinezumab were 0.00620 L h^−1^ (0.15 L day^−1^) and 3.64 L, respectively. The *C* ~max~ for eptinezumab was 37.3 μg mL^−1^ following a single IV administration of 100 mg and 114 μg mL^−1^ after a single dose of 300 mg. The median time to *C* ~max~ (*T* ~max~) was 30 minutes for a 30‐minute IV administration and 60 minutes for a 60‐minute IV administration (ie, immediately after the completion of the IV delivery). The elimination half‐lives of eptinezumab associated with the α and β phases were 0.93 and 27 days, respectively. All parameters were estimated with the population PK model since relative standard error (RSE) values were less than 20%. Between‐subject variability was 29% for CL and 31% for Vc. In addition, the residual variability of the model (ie, the sum of all variability not explained by the model) was 37.5 ng mL^−1^ (RSE = 5.7%).

Body weight, creatinine clearance (CL~cr~, capped at a physiological value of 150 mL min^−1^), disease state (healthy, EM, CM), and baseline migraine days were the most important covariates describing the variability of eptinezumab CL; the covariates of age, sex, race, dose, immunogenicity (presence of ADAs and NAbs), and concomitant preventive headache/migraine dropped out during covariate selection for eptinezumab CL. Body weight, disease state (healthy, EM, CM), and sex were the covariates describing the variability of Vc for eptinezumab; the covariates of age, body weight, race, dose, baseline migraine days, immunogenicity (presence of ADAs and NAbs), and concomitant preventive headache/migraine dropped out during covariate selection for eptinezumab Vc. The effect of covariates in the final model is illustrated in Figure [4](#prp2567-fig-0004){ref-type="fig"}. Body weight was the covariate with the greatest influence on AUC~0‐τ~, and the final PK model included an allometric function of body weight on clearance. Overall, the presence of ADAs or NAbs were not important covariates describing the variability of eptinezumab PK parameters and were not retained as a covariate in the eptinezumab PK model during the covariate analysis. The 95% confidence intervals for the median ratios were generally contained within 0.8‐1.20 (Figure [4](#prp2567-fig-0004){ref-type="fig"}). As such, the effect of most covariates was within 20% of healthy, with the exception of disease state, as well as the minimum and maximum values of body weights of the population used in the population PK analyses (ie, 39 and 190 kg, respectively).

![Geometric mean ratios (90% CI) for the effect of covariates on eptinezumab exposure at steady state (AUC~0‐τ~). For the continuous covariates (baseline MMD \[MDBASE\], body weight and CL~or_cap~) the minimum, 25th quantile, median, 75th quantile, and maximum values of the population are presented on the *y*‐axis. In addition, the typical body weight for an adult male (70 kg) was presented for the continuous covariate of body weight. On the right, the changes in exposure to eptinezumab are presented as median ratios and associated 95% confidence intervals. The dotted vertical line marks the AUC~0‐τ~ for a typical patient (healthy female subject, weight = 70 kg; CL~or_cap~ = 118 mL min^−1^, baseline MMD of 13 days). The effects of "test" covariates are presented relative to the aforementioned reference AUC~0‐τ~. AUC~0‐τ~, area under concentration‐time curve during a dosing interval (12 weeks) at steady state; CL~or_cap~, creatinine clearance capped at a physiological value of 150 mL min^−1^; CM, chronic migraine; EM, episodic migraine; MMD, monthly migraine days](PRP2-8-e00567-g004){#prp2567-fig-0004}

Extreme body weights of 39 and 190 kg, as well as patients with EM or CM are therefore expected to show eptinezumab exposure levels that are statistically lower/higher compared to the typical healthy adult. However, there has not been a safety issue identified with higher eptinezumab exposure. Therefore, higher AUC is not expected to be associated with a safety issue. Moreover, a steep dose‐response curve was observed (Figure [5](#prp2567-fig-0005){ref-type="fig"}A). There was a plateau of effect for exposures associated with doses \>100 mg, whereas the second quartile of AUC~0‐12wk~ (corresponding to \~30‐mg doses of eptinezumab) showed similar probability of response. Thus, assuming a clinical dose of 100 mg, a reduction of 50% in AUC is not expected to have a large impact on the efficacy of eptinezumab. Finally, there was negligible difference in eptinezumab exposure ratios for patients with chronic migraine vs patients with episodic migraine, as well as negligible differences in the dose‐response curves when split by disease state (Figure [5](#prp2567-fig-0005){ref-type="fig"}B). PK parameters derived from the population PK model of eptinezumab after single and multiple doses are presented in Tables [2](#prp2567-tbl-0002){ref-type="table"} and [3](#prp2567-tbl-0003){ref-type="table"}, respectively.

![Overall dose‐response relationship (A) and dose‐response relationship by disease status (chronic migraine vs episodic migraine; B). The solid lines with gray shaded area are smooth (loess) regression and 95% confidence interval. CM, chronic migraine; EM, episodic migraine; MMD, monthly migraine days](PRP2-8-e00567-g005){#prp2567-fig-0005}

###### 

Pharmacokinetic parameters of eptinezumab following a 30‐minute to 1‐hour IV administration (single dose)

  PK parameter                           Eptinezumab dose (mg)                                                                                 
  -------------------------------------- ----------------------- --------------- -------------- -------------- --------------- --------------- ----------------
  AUC~0‐12wk~, mean (CV%), h·μg mL^−1^   158 (57.9)              251 (24.4)      2050 (47.3)    5770 (41.1)    17 900 (29.0)   54 500 (27.7)   164 000 (24.0)
  *C* ~max~, mean (CV%), μg mL^−1^       0.279 (59.0)            0.460 (29.7)    4.32 (56.8)    12.4 (38.6)    37.3 (28.1)     114 (27.7)      348 (22.4)
  *C* ~avg~, mean (CV%), μg mL^−1^       0.0785 (57.9)           0.124 (24.4)    1.02 (47.3)    2.87 (41.2)    8.95 (29.3)     27.2 (27.8)     81.3 (24.0)
  *C* ~trough~, mean (CV%), μg mL^−1^    0.0232 (60.2)           0.0333 (18.8)   0.294 (50.6)   0.821 (55.4)   2.66 (46.1)     8.06 (42.4)     23.3 (34.7)

A total of 5 patients/subjects received IV administrations over approximately 2 hours.

Abbreviations: AUC~0‐12wk~, area under the concentration‐time curve from time zero to 12 weeks; *C* ~avg~, average concentration; *C* ~max~, maximum concentration; *C* ~trough~, concentration observed at the end of the dosing interval (12 weeks); CV%, coefficient of variation.
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###### 

Pharmacokinetic parameters of eptinezumab following a 30‐minute to 1‐hour IV administration (steady state)

  PK parameter                        Eptinezumab dose (mg)                                                                              
  ----------------------------------- ----------------------- -------------- ------------- ------------- --------------- --------------- ----------------
  AUC~0‐τ~, mean (CV%), h·μg mL^−1^   183 (60.0)              282 (23.0)     2350 (47.5)   6640 (43.3)   20 800 (32.1)   63 100 (30.1)   187 000 (25.4)
  C~ss,avg~, mean (CV%), μg mL^−1^    0.0910 (60.0)           0.140 (23.0)   1.17 (47.5)   3.29 (43.3)   10.3 (32.1)     31.1 (30.1)     93.0 (25.4)
  R~ac~(AUC~τ~), mean (CV%)           1.15 (1.9)              1.13 (3.3)     1.14 (4.0)    1.14 (6.6)    1.15 (7.7)      1.15 (6.3)      1.14 (3.8)
  R~ac~(*C* ~max~), mean (CV%)        1.10 (0.68)             1.09 (2.8)     1.08 (2.4)    1.08 (2.9)    1.08 (3.7)      1.08 (3.2)      1.08 (2.1)

A total of five patients/subjects received IV administrations over approximately 2 hours. Steady state was achieved after the second dose.

Abbreviations: AUC~0‐τ~, area under concentration‐time curve during a dosing interval (12 weeks) at steady state; C~ss,avg~, average steady‐state drug concentration during a dosing interval; CV%, coefficient of variation; R~ac~(AUC~τ~), accumulation ratio based on AUC~τ~; R~ac~(*C* ~max~), accumulation ratio based on *C* ~max~.
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3.3. Dose‐ and exposure‐response analyses {#prp2567-sec-0012}
-----------------------------------------

The eptinezumab dose‐response relationship for change in the frequency of MMD (primary endpoint) over weeks 1‐12 is illustrated in Figure [6](#prp2567-fig-0006){ref-type="fig"}. As seen in the figure, the treatment benefit is most pronounced at dose levels 100 mg and higher. Overall, the dose‐response curves for patients with CM (studies CLIN‐005 and CLIN‐011) were similar to curves for patients with EM (study CLIN‐006), although the slope of the curve was somewhat steeper for patients with CM vs those with EM (Figure [3](#prp2567-fig-0003){ref-type="fig"}B). Doses of 100 mg or greater were generally associated with greater reductions in migraine days from baseline for both EM and CM. Figure [6](#prp2567-fig-0006){ref-type="fig"} illustrates the exposure‐response relationship for AUC~0‐12wk~. An AUC~0‐12wk~ of 15 000 h·μg mL^−1^ or higher tended to produce a sustained decrease in migraine days compared with baseline. This exposure corresponds to the average AUC~0‐12wk~ after administration of a 100‐mg IV dose of eptinezumab. Similar decreases in the number of migraine days were observed for increasing *C* ~max~, *C* ~avg~, and *C* ~trough~ (data not shown).

![Exposure‐response relationship over weeks 1‐12. The solid line with gray shaded area is smooth (loess) regression and 95% confidence interval. AUC~0‐12wk~, area under the concentration‐time curve from time zero to 12 weeks; MMD, monthly migraine days](PRP2-8-e00567-g006){#prp2567-fig-0006}

Table [4](#prp2567-tbl-0004){ref-type="table"} summarizes the results of the saturable inhibitory *E* ~max~ model used to assess the relationship between eptinezumab exposure metrics and change in the frequency of MMD over weeks 1‐12. Treatment with single doses of eptinezumab 100 or 300 mg provided exposures (AUC~0‐12wk~, *C* ~max~, *C* ~avg~, and *C* ~trough~) that exceeded the amount required to achieve 90% of the maximal efficacy (EC~90~) estimates for patients with either EM or CM. In contrast, doses of 30 mg or lower provided exposures that were below EC~90~ estimates for patients with either EM or CM.

###### 

Inhibitory *E* ~max~ model‐derived parameters: PK/PD exposure correlation of change in frequency of mean migraine days at weeks 1‐12 vs eptinezumab exposure parameters after a single dose

  Eptinezumab exposure metric   Disease state   EC~50~ (CV%)    EC~90~ [a](#prp2567-note-0007){ref-type="fn"}   Mean (CV%) PK parameters following a single dose                   
  ----------------------------- --------------- --------------- ----------------------------------------------- -------------------------------------------------- --------------- ---------------
  AUC~0‐12wk~, h·μg mL^−1^      CM              1480 (85.6)     13 300                                          5770 (41.1)                                        17 900 (29.0)   54 500 (27.7)
  EM                            1190 (225.7)    10 700                                                                                                                             
  *C* ~max~, μg mL^−1^          CM              3.78 (84.0)     34.0                                            12.4 (38.6)                                        37.3 (28.1)     114 (27.7)
  EM                            2.54 (228.4)    22.8                                                                                                                               
  *C* ~trough~, μg mL^−1^       CM              0.109 (105.6)   0.983                                           0.821 (55.4)                                       2.66 (46.1)     8.06 (42.4)
  EM                            0.183 (187.7)   1.65                                                                                                                               
  *C* ~avg~, ng mL^−1^          CM              745 (85.7)      6710                                            2870 (41.2)                                        8950 (29.3)     27 200 (27.8)
  EM                            585 (227.3)     5260                                                                                                                               

Abbreviations: AUC~0‐12wk~, area under the concentration‐time curve from time zero to 12 weeks; *C* ~avg~, average concentration; CM, chronic migraine; *C* ~max~, maximum concentration; *C* ~trough~, concentration observed at the end of the dosing interval (12 weeks); CV%, coefficient of variation; EC~50~, concentration achieving the half‐maximal change in effect; EC~90~, concentration achieving 90% of the maximum change in effect; EM, episodic migraine; *E* ~max~, maximum inhibitory effect; PD, pharmacodynamic; PK, pharmacokinetic.

Predicted from the EC~50~ fitted from the inhibitory *E* ~max~ model.
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The exposure‐response analysis for secondary endpoints supports the results of the primary endpoint analysis (Figure [7](#prp2567-fig-0007){ref-type="fig"}). This included analyses of the relationship between eptinezumab exposure (AUC~0‐12wk~) and various categorical endpoints (ie, ≥75% migraine responder rate \[weeks 1‐4\], ≥75% migraine responder rate \[weeks 1‐12\], and ≥50% migraine responder rate \[weeks 1‐12\]; Figure [7](#prp2567-fig-0007){ref-type="fig"}A‐C). Overall, there was a statistically significant effect of eptinezumab exposure and these endpoints (*P* \< .05 for all three comparisons). In particular, the third quartile of AUC~0‐12wk~ (corresponding to an \~100‐mg dose of eptinezumab) appeared to show a higher probability of response for all secondary endpoints, compared to the first and second quartiles of AUC~0‐12wk~ (corresponding to \~10 and 30‐mg doses of eptinezumab, respectively). There was a plateau of effect for exposures associated with doses \>100 mg.

![Exposure‐response relationship for secondary endpoints. (A) ≥75% migraine responder rate (weeks 1‐4) vs AUC~0‐4wk~; (B) ≥75% migraine responder rate (weeks 1‐12) vs AUC~0‐12wk~; and (C) ≥50% migraine responder rate (weeks 1‐12) vs AUC~0‐12wk~. For each quartile of eptinezumab exposure: Range, the minimum and maximum values; N responder, total number of subjects with a response; Total N, total number of subjects in each quartile of eptinezumab exposure; Proportion, N responder/Total N For each quartile of eptinezumab exposure: the minimum and maximum values are presented next to the distribution of exposure for each quartile of eptinezumab exposure. (A) Slope \[95% confidence interval\]: 0.428 \[0.28922, 0.56589\], *P* \< .0001. (B) Slope \[95% confidence interval\]: 0.35367 \[0.22059, 0.48675\]; *P* \< .0001. (C) Slope \[95% confidence interval\]: 0.36708 \[0.2429, 0.4912\]; *P* \< .0001](PRP2-8-e00567-g007){#prp2567-fig-0007}

4. DISCUSSION {#prp2567-sec-0013}
=============

Monoclonal antibodies targeted against the CGRP ligand or receptor represent a mechanism‐based approach to therapy that specifically targets the initiation and transmission of migraine.[4](#prp2567-bib-0004){ref-type="ref"}, [20](#prp2567-bib-0020){ref-type="ref"} There are currently three mAbs that inhibit CGRP biology (erenumab, fremanezumab, and galcanezumab) approved for prevention of migraine in the United States, with eptinezumab currently under regulatory review. Differences exist between these mAbs in pharmacokinetics and in binding characteristics that have the potential to influence efficacy and tolerability.[21](#prp2567-bib-0021){ref-type="ref"}, [22](#prp2567-bib-0022){ref-type="ref"}, [23](#prp2567-bib-0023){ref-type="ref"}, [24](#prp2567-bib-0024){ref-type="ref"} These pharmacologic differences likely explain the dosing regimens of the available agents. Some agents require a loading dose (ie, galcanezumab) and some are administered monthly (ie, galcanezumab, erenumab) rather than every 12 weeks.[25](#prp2567-bib-0025){ref-type="ref"}, [26](#prp2567-bib-0026){ref-type="ref"}, [27](#prp2567-bib-0027){ref-type="ref"}, [28](#prp2567-bib-0028){ref-type="ref"}, [29](#prp2567-bib-0029){ref-type="ref"} Fremanezumab can be administered either monthly or quarterly, with the quarterly dosing requiring three separate injections.[30](#prp2567-bib-0030){ref-type="ref"}

Eptinezumab was designed to provide rapid and sustained efficacy due to the targeting of the soluble CGRP ligand with high selectivity and affinity paired with a IV route of administration every 12 weeks.[14](#prp2567-bib-0014){ref-type="ref"} Overall, the concentration‐time profile of eptinezumab was adequately characterized by a two‐compartment model. Consistent with other mAbs, eptinezumab has linear elimination characteristics (CL = 0.15 L day^−1^) and a small Vc (3.64 L).[19](#prp2567-bib-0019){ref-type="ref"} The most important covariates describing the variability of eptinezumab CL were body weight, renal function, disease state (healthy, EM, CM), and baseline MMDs, whereas the most important covariates describing the variability of Vc were body weight, disease, and sex. Although these effects are noted, the relatively small changes in CL and Vc do not suggest that dosage adjustments are necessary. These findings are in line with other mAbs that inhibit the CGRP biology (ie, galcanezumab, fremanezumab, erenumab) for which these patient characteristics do not produce clinically meaningful changes in any PK parameters.[31](#prp2567-bib-0031){ref-type="ref"}

The population PK model indicates that eptinezumab doses of 100 mg produce mean *C* ~max~ and AUC~0‐12wk~ values of \>37 μg mL^−1^ and \>17 000 h·μg mL^−1^, respectively, with a terminal elimination half‐life of 27 days. As anticipated for the IV route of administration, eptinezumab had a short *T* ~max~ of 30 to 60 minutes, which corresponded with the end of the IV delivery. This rapid achievement of *C* ~max~ may provide a pharmacokinetic explanation for the rapid onset of effect observed in clinical trials.[12](#prp2567-bib-0012){ref-type="ref"}, [13](#prp2567-bib-0013){ref-type="ref"} The short *T* ~max~ values for eptinezumab are in contrast to the longer median values for single doses of erenumab (4‐11 days),[23](#prp2567-bib-0023){ref-type="ref"} fremanezumab (5‐11 days),[21](#prp2567-bib-0021){ref-type="ref"} and galcanezumab (7‐14 days),[22](#prp2567-bib-0022){ref-type="ref"} which are administered subcutaneously. Delivery by the subcutaneous route of administration requires time for absorption, a process that is also associated with a loss of active drug or reduced bioavailability.[32](#prp2567-bib-0032){ref-type="ref"} Due to these issues, subcutaneous administration can lead to the need to administer higher doses, more frequent administration, or a combination of both in order to achieve and maintain therapeutic exposure.

The exposure‐response analysis demonstrated a trend toward increased efficacy with increased exposure. Exposure following the administration of eptinezumab 30 mg or less was insufficient to meet the EC~90~ estimates for change in the frequency of MMD. Furthermore, although the number of patients evaluated that received 30 mg was lower (n = 330) than the number receiving 100 mg (n = 691) or 300 mg (n = 687), measures of efficacy from the model (EC~50~ for AUC~0‐12wk~ exposures) suggested that doses greater than 30 mg would be required to achieve a plateau for statistically reducing the number of migraine days over weeks 1‐12. As eptinezumab doses increased to 100 mg, there was an increased probability of a reduction in the frequency of MMD over weeks 1‐12, with a plateau of effect as the dose was further increased to 300 mg. This similar efficacy between the 100‐mg and 300‐mg doses supports the notion of a lowest effective dose of 100 mg.

In general, an AUC~0‐12wk~ of 15 000 h·μg mL^−1^ or higher tended to produce a sustained decrease in migraine days compared to baseline. Notably, this level is below the average AUC~0‐12wk~ produced by a single 100‐mg dose (ie, 17 900 h·μg mL^−1^). In the inhibitory *E* ~max~ model, the relationship between the change in frequency of MMD over weeks 1‐12 vs key metrics of exposure revealed that treatment with a single 100‐mg or 300‐mg dose of eptinezumab provided exposures (AUC~0‐12wk~, *C* ~max~, *C* ~trough~, or *C* ~avg~) that exceeded all EC~90~ estimates for the EM and CM groups. In contrast, the exposure values produced by the eptinezumab 30‐mg dose or lower were below EC~90~ values for both EM and CM. The results of the exposure‐response analysis for secondary endpoints reinforced the less robust response at the 30‐mg dose level and the presence of a plateau effect between 100 and 300 mg. This suggests that doses of 100 and 300 mg would result in similar efficacy.

A similar exposure‐response analysis conducted with the anti‐CGRP mAb galcanezumab that used a lower threshold for efficacy (EC~50~) revealed that the EC~50~ related to the rate of dissipation of migraine headache days per month was achieved only at some dose levels and only for a portion of the dosing interval.[33](#prp2567-bib-0033){ref-type="ref"} In data from the FDA drug‐approval package, the population PK estimated EC~50~ for galcanezumab was 43.9 μg mL^−1^, a level that is achieved only via 240‐mg monthly dosing and only for approximately half of the dosing interval (as measured by the median concentration).[33](#prp2567-bib-0033){ref-type="ref"} This finding may have clinical relevance because it suggests that patients may not be achieving drug concentrations adequate to prevent migraines for significant portions of the dosing interval. Exposure‐response information for erenumab provided in the FDA drug‐approval package indicated that an estimated plasma concentration of 5.1 μg mL was required to achieve the EC~50~ for reduction in the probability of MMD in EM patients.[34](#prp2567-bib-0034){ref-type="ref"} No patients receiving a 70‐mg dose of erenumab reached EC~50~ exposure levels on the first day of dosing, and 64% achieved EC~50~ exposure levels within the first week of administration.[34](#prp2567-bib-0034){ref-type="ref"} For fremanezumab, the maximal fractional reduction in MMD was described by an *E* ~max~ function with only plasma concentration over the dosing interval, *C* ~avg~, provided as an exposure metric. The average concentration required to achieve the EC~50~ was estimated to be 3.6 μg mL^−1^.[35](#prp2567-bib-0035){ref-type="ref"} The less than optimal exposure‐response results associated with these anti‐CGRP agents may be at least partially explained by the PK profiles associated with their subcutaneous administration, which results in a longer time to *T* ~max~ and incomplete bioavailability. This contrasts with the high binding affinity and IV administration of eptinezumab, which has 100% bioavailability and a *T* ~max~ at the end of the IV administration, resulting in faster and robust achievement of therapeutically effective concentrations.

5. CONCLUSIONS {#prp2567-sec-0014}
==============

This population PK and exposure‐response analysis demonstrates that eptinezumab exhibits linear pharmacokinetics, with *C* ~max~ achieved at the end of the IV administration (*T* ~max~). The relatively low exposure metrics required to achieve EC~90~ and half‐life of 27 days support less frequent, every 12 weeks, IV administration with 100 mg or greater. The relatively small change in clearance associated with patient‐related factors (eg, body weight), the absence of dose‐limiting toxicity, and the relatively flat exposure response at doses of 100‐300 mg support that there is no need for dose adjustments for patient‐related factors. There was increased efficacy for both the primary and secondary endpoints with increased exposure of eptinezumab followed by a plateau of effect. The 100‐mg and 300‐mg doses provide exposures that exceed the EC~90~ estimates for AUC~0‐12wk~, *C* ~max~, *C* ~avg~, and *C* ~trough~ in both EM and CM patients. These data demonstrate that eptinezumab 100 mg, administered every 12 weeks, is an appropriate dosing regimen for patients with episodic or chronic migraine.
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